Daily News Briefs
Corning Inc. has been granted a license for patent rights to reverse transfection method technology for the drug discovery research market by the
Whitehead Institute for Biomedical Research, through Massachusetts Institute of Technology (MIT), its licensing agent. Corning will use the intellectual property with fundamental technology it previously licensed from Aastrom Biosciences Inc. to enhance the development of its molecular and cell culture applications. Corning holds exclusive rights to Aastrom's surface-mediated cell transfection technology, used to increase the frequency and efficiency of introducing foreign genes into cells.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024